Literature DB >> 15762935

Low incidence of infectious complications after nonmyeloablative compared with myeloablative allogeneic stem cell transplantation.

E Meijer1, A W Dekker, H M Lokhorst, E J Petersen, H K Nieuwenhuis, L F Verdonck.   

Abstract

Allogeneic stem cell transplantation (SCT) using a myeloablative (MA) conditioning regimen is limited to relatively young patients because of increased transplant-related mortality in elderly patients. Nonmyeloablative (NMA) conditioning regimens have been developed aiming to reduce transplant mortality. In this study, we set out to evaluate the post-transplant occurrence of infectious complications in recipients of grafts from human leukocyte antigen (HLA)-identical sibling donors treated with either NMA or MA conditioning regimens. Data of 78 consecutively treated patients were analyzed. An NMA conditioning regimen was used in 40 patients and an MA regimen in 38 patients. A significantly lower rate of episodes of febrile neutropenia (0% vs. 34%, P<0.01) and post-transplant Epstein-Barr virus reactivations (0% vs. 18%, P<0.05) was found in SCT recipients treated with an NMA conditioning regimen compared with an MA conditioning regimen. Furthermore, fewer invasive fungal infections (2% vs. 12%, not significant) were diagnosed in the NMA group. The incidence of cytomegalovirus (CMV) reactivations and bacterial infections was low in both groups (CMV reactivations: 13% in both groups; bacterial infections: 10% in the NMA group vs. 8% in the MA group), while CMV disease developed in only 1 patient. Overall, compared to our MA regimen, we found a very low rate of infectious complications after NMA SCT.

Entities:  

Mesh:

Year:  2004        PMID: 15762935     DOI: 10.1111/j.1399-3062.2004.00075.x

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  10 in total

1.  High incidence of herpes zoster in nonmyeloablative hematopoietic stem cell transplantation.

Authors:  Shih Hann Su; Valérie Martel-Laferrière; Annie-Claude Labbé; David R Snydman; David Kent; Michel Laverdière; Claire Béliveau; Tanya Logvinenko; Sandra Cohen; Silvy Lachance; Thomas Kiss; Jean Roy
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-25       Impact factor: 5.742

2.  Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Authors:  Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2009-10       Impact factor: 5.742

3.  Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1.

Authors:  Celalettin Ustun; Soyoung Kim; Min Chen; Amer M Beitinjaneh; Valerie I Brown; Parastoo B Dahi; Andrew Daly; Miguel Angel Diaz; Cesar O Freytes; Siddhartha Ganguly; Shahrukh Hashmi; Gerhard C Hildebrandt; Hillard M Lazarus; Taiga Nishihori; Richard F Olsson; Kristin M Page; Genovefa Papanicolaou; Ayman Saad; Sachiko Seo; Basem M William; John R Wingard; Baldeep Wirk; Jean A Yared; Miguel-Angel Perales; Jeffery J Auletta; Krishna V Komanduri; Caroline A Lindemans; Marcie L Riches
Journal:  Blood Adv       Date:  2019-09-10

4.  Inhibition of aldehyde dehydrogenase expands hematopoietic stem cells with radioprotective capacity.

Authors:  Garrett G Muramoto; J Lauren Russell; Rachid Safi; Alice B Salter; Heather A Himburg; Pamela Daher; Sarah K Meadows; Phuong Doan; Robert W Storms; Nelson J Chao; Donald P McDonnell; John P Chute
Journal:  Stem Cells       Date:  2010-03-31       Impact factor: 6.277

Review 5.  Promising role of reduced-toxicity hematopoietic stem cell transplantation (PART-I).

Authors:  S Abdul Wahid Fadilah; Md Pazil Aqilah
Journal:  Stem Cell Rev Rep       Date:  2012-12       Impact factor: 5.739

Review 6.  Immune deficits in allogeneic hematopoietic stem cell transplant (HSCT) recipients.

Authors:  Muhammad A Mir; Minoo Battiwalla
Journal:  Mycopathologia       Date:  2009-01-21       Impact factor: 2.574

7.  Fluoroquinolone prophylaxis in patients with neutropenia: a meta-analysis of randomized placebo-controlled trials.

Authors:  H Imran; I M Tleyjeh; C A S Arndt; L M Baddour; P J Erwin; C Tsigrelis; N Kabbara; V M Montori
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-10-16       Impact factor: 3.267

Review 8.  Antibacterial Resistance in Patients with Hematopoietic Stem Cell Transplantation.

Authors:  Sehnaz Alp; Murat Akova
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-01-01       Impact factor: 2.576

9.  Allogeneic stem cell transplantation for patients with advanced hematological malignancies: comparison of fludarabine-based reduced intensity conditioning versus myeloablative conditioning.

Authors:  Inho Kim; Kyung-Hun Lee; Yunhee Choi; Bhumsuk Keam; Nam Hee Koo; Sung-Soo Yoon; Keun-Young Yoo; Seonyang Park; Byoung Kook Kim
Journal:  J Korean Med Sci       Date:  2007-04       Impact factor: 2.153

Review 10.  Factors Associated with Post-Transplant Active Epstein-Barr Virus Infection and Lymphoproliferative Disease in Hematopoietic Stem Cell Transplant Recipients: A Systematic Review and Meta-Analysis.

Authors:  Pascal Roland Enok Bonong; Monica Zahreddine; Chantal Buteau; Michel Duval; Louise Laporte; Jacques Lacroix; Caroline Alfieri; Helen Trottier
Journal:  Vaccines (Basel)       Date:  2021-03-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.